Search

everythinglearnresearchcommunity

for

Search:↓

Researchers developed a model to predict how well certain compounds can block an enzyme related to hair loss and prostate issues, suggesting a 50 mg dose of finasteride might be effective based on lab and body data.

Different halogens on progesterone derivatives can either block or mimic male hormone effects, depending on their type and amount.

Changing the C-ring structure in certain compounds can make them better at blocking a specific human enzyme.

Some new progesterone derivatives are better at blocking testosterone conversion than a common drug.

New compounds similar to cromakalim were less effective at inhibiting insulin release but improved in solubility and one acted as a calcium entry blocker, not a potassium channel opener.

The research shows that hydrogen bonds greatly affect the crystal structure of a Finasteride derivative.

Certain compounds, especially those with a propionic substituent, could potentially be new treatments for hair loss and similar disorders.

Compound 7p shows strong potential as an anticancer agent.

Certain compounds reduced hamster flank organ size by inhibiting 5α-reductase, like finasteride, without affecting androgen receptors.

Changing the 6-position on benzopyran molecules affects insulin release, with some compounds showing strong inhibitory effects.

Adding cerium(III) chloride to Grignard reagents improves the making of compounds that could treat prostate issues and hair loss.

Certain changes to the B-ring of androgen receptor ligands can increase their effectiveness for potential treatments of muscle and bone conditions.

New compounds were made that effectively block enzymes related to prostate issues and hair loss.

The study created a model to help design new inhibitors for steroidal 5α-reductase enzymes.

Scientists made the first metal-based compounds from a nonsteroidal antiandrogen drug, which showed potential in fighting both hormone-dependent and independent prostate cancer cells.

Three specific 4-azasteroid-2-oximes showed strong enzyme inhibition, but less than finasteride.

New compounds were made that effectively block a specific enzyme related to androgen conditions.

Selective non-steroidal inhibitors of 5α-reductase type 1 can help treat DHT-related disorders.

Certain inhibitors can potentially treat prostate cancer and other hormone-dependent conditions by controlling sex hormone levels in cells.

The new compounds moderately block a specific enzyme and strongly counteract a male hormone, suggesting potential for treating certain male-related health conditions.

Certain drugs that block specific enzymes can help treat prostate diseases.

A new compound shows promise as a topical treatment for hair loss.

New compounds were made that block an enzyme linked to breast cancer better than existing treatments.

Benzo[c]quinolizin-3-ones are effective nonsteroidal inhibitors of human steroid 5α-reductase 1.

New research is needed to create better drugs that block the enzyme responsible for conditions like male baldness and prostate enlargement.

New treatments for prostate cancer and BPH show promise, including novel compounds that target hormone synthesis and response.

New treatments for enlarged prostate are being developed, some of which may be more effective than current medications.

New steroidal compounds moderately block an enzyme related to testosterone conversion, less effectively than finasteride.

The document highlights various patents for new compounds with potential treatments for multiple diseases, including cancer, hormonal disorders, and diabetes.

New treatments for Hepatitis C show promise but need more research to confirm their safety and effectiveness for clinical use.